University of Toronto agrees to drop objections to proposed Connaught acquisition by French vaccine developer Institut Merieux, which will grant the university $9 mil. (Canadian) for vaccine research and an additional C $6 mil. to other Canadian institutions. The deal represents a substantial increase over an existing agreement in which the university received C $400,000 from Connaught in 1988. On Oct. 27, Institut Merieux extended its C $37 per share offer for Connaught stock. Ciba-Geigy and Chiron, which have an outstanding offer for Connaught of C $30 per share, also presented a similar investment agreement to the university. Ontario Supreme Court said Oct. 27 that it is delaying ruling on university's lawsuit against Connaught because of the agreement-in-principle reached in the dispute....
You may also be interested in...
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The sentences are the latest chapter in a long-running off-label marketing case.